TY - JOUR
T1 - Longitudinal outcome of attenuated positive symptoms, negative symptoms, functioning and remission in people at clinical high risk for psychosis
T2 - a meta-analysis
AU - Salazar de Pablo, Gonzalo
AU - Besana, Filippo
AU - Arienti, Vincenzo
AU - Catalan, Ana
AU - Vaquerizo-Serrano, Julio
AU - Cabras, Anna
AU - Pereira, Joana
AU - Soardo, Livia
AU - Coronelli, Francesco
AU - Kaur, Simi
AU - da Silva, Josette
AU - Oliver, Dominic
AU - Petros, Natalia
AU - Moreno, Carmen
AU - Gonzalez-Pinto, Ana
AU - Díaz-Caneja, Covadonga M.
AU - Shin, Jae Il
AU - Politi, Pierluigi
AU - Solmi, Marco
AU - Borgatti, Renato
AU - Mensi, Martina Maria
AU - Arango, Celso
AU - Correll, Christoph U.
AU - McGuire, Philip
AU - Fusar-Poli, Paolo
N1 - Funding Information:
Prof McGuire and Prof Fusar-Poli are supported by the PSYSCAN project through the European commission. Dr Salazar de Pablo and Dr Vaquerizo Serrano are supported by the Alicia Koplowitz Foundation. Dr Moreno, Prof Arango, and Dr D?az-Caneja are supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III, European Regional Development Fund ?A way of making Europe?, Centro de Investigaci?n Biom?dica en Red Salud Mental, Madrid Regional Government; and Fundaci?n Mutua Madrile?a.
Funding Information:
Dr Salazar de Pablo has received honoraria from Janssen Cilag and grants from Alicia Koplowitz Foundation. Dr Vaquerizo-serrano has received grants from Alicia Koplowitz Foundation. Dr Moreno has been a consultant to or has received honoraria from Janssen Cilaq, Angelini, Servier, Nuvelution, Otsuka, Lundbeck, Pfizer and Esteve outside the submitted work. Prof Gonzalez-Pinto has received grants from the Spanish Ministry of Science and the European Framework and has been a consultant to or has received honoraria from Janssen-Cilag, Angelini, and Roche, support for attending meetings from Janssen, partecipations n a data advisory board for Jenssen, Takeda and Angelini and is president of the Spanish society of Biological Psichiatry and of the Spanish Foundation of Psichiatry and mental health. Dr Díaz-Caneja has received honoraria from AbbVie, Sanofi, Exeltis and Lundbeck. Dr Solmi has been a consultant to or has received honoraria from Angelini and Lundbeck. Prof Arango has received grants or contracts from Bristol-Myers Squibb, Narsad, Sumitomo Dainipon Pharma and Stanley Foundation. He has been a consultant to or has received honoraria or grants from Acadia, Angelini, AstraZeneca, Bristol-Myers Squibb, Gedeon Richter, Janssen Cilag, Lundbeck, Otsuka, Roche, Sage, Servier, Shire, Schering Plough, Stanley Foundation, Takeda and Alicia Koplowitz Foundation. Prof Correll has been receiving grants from Janssen, royalties form UpToDate, consulting fees from Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva, payment or honoraria for lectures from Angelini, Gedeon Richter, Janssen/J&J, Lundbeck, Mitsubishi Tanabe Pharma, Mylan, Sumitomo Dainippon. Otsuka, Recordati, Sunovion (no speakers bureau), payment for expert testimony from Janssen and Otsuka, participation on a data safety monitoring Board for Lundbeck, Rovi, Supernus, and Teva, leadership or fiduciary role in other boards for ASCP, receipt of equipment from Takeda and is a shareholder of LB Pharma.
Funding Information:
Prof McGuire and Prof Fusar-Poli are supported by the PSYSCAN project through the European commission. Dr Salazar de Pablo and Dr Vaquerizo Serrano are supported by the Alicia Koplowitz Foundation. Dr Moreno, Prof Arango, and Dr Díaz-Caneja are supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III, European Regional Development Fund ‘A way of making Europe’, Centro de Investigación Biomédica en Red Salud Mental, Madrid Regional Government; and Fundación Mutua Madrileña.
Publisher Copyright:
© 2021 The Authors
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/6
Y1 - 2021/6
N2 - Background: Little is known about clinical outcomes other than transition to psychosis in people at Clinical High-Risk for psychosis (CHR-P). Our aim was to comprehensively meta-analytically evaluate for the first time a wide range of clinical and functional outcomes beyond transition to psychosis in CHR-P individuals. Methods: PubMed and Web of Science were searched until November 2020 in this PRISMA compliant meta-analysis (PROSPERO:CRD42020206271). Individual longitudinal studies conducted in individuals at CHR-P providing data on at least one of our outcomes of interest were included. We carried out random-effects pairwise meta-analyses, meta-regressions, and assessed publication bias and study quality. Analyses were two-tailed with α=0.05. Findings: 75 prospective studies were included (n=5,288, age=20.0 years, females=44.5%). Attenuated positive symptoms improved at 12 (Hedges’ g=0.753, 95%CI=0.495-1.012) and 24 (Hedges’ g=0.836, 95%CI=0.463-1.209), but not ≥36 months (Hedges’ g=0.315. 95%CI=-0.176–0.806). Negative symptoms improved at 12 (Hedges’ g=0.496, 95%CI=0.315–0.678), but not 24 (Hedges’ g=0.499, 95%CI=-0.137–1.134) or ≥36 months (Hedges’ g=0.033, 95%CI=-0.439–0.505). Depressive symptoms improved at 12 (Hedges’ g=0.611, 95%CI=0.441–0.782) and 24 (Hedges’ g=0.583, 95%CI=0.364–0.803), but not ≥36 months (Hedges’ g=0.512 95%CI=-0.337–1.361). Functioning improved at 12 (Hedges’ g=0.711, 95%CI=0.488–0.934), 24 (Hedges’ g=0.930, 95%CI=0.553–1.306) and ≥36 months (Hedges’ g=0.392, 95%CI=0.117–0.667). Remission from CHR-P status occurred in 33.4% (95%CI=22.6–44.1%) at 12 months, 41.4% (95%CI=32.3–50.5%) at 24 months and 42.4% (95%CI=23.4–61.3%) at ≥36 months. Heterogeneity across the included studies was significant and ranged from I2=53.6% to I2=96.9%. The quality of the included studies (mean±SD) was 4.6±1.1 (range=2-8). Interpretation: CHR-P individuals improve on symptomatic and functional outcomes over time, but these improvements are not maintained in the longer term, and less than half fully remit. Prolonged duration of care may be needed for this patient population to optimize outcomes. Funding: None.
AB - Background: Little is known about clinical outcomes other than transition to psychosis in people at Clinical High-Risk for psychosis (CHR-P). Our aim was to comprehensively meta-analytically evaluate for the first time a wide range of clinical and functional outcomes beyond transition to psychosis in CHR-P individuals. Methods: PubMed and Web of Science were searched until November 2020 in this PRISMA compliant meta-analysis (PROSPERO:CRD42020206271). Individual longitudinal studies conducted in individuals at CHR-P providing data on at least one of our outcomes of interest were included. We carried out random-effects pairwise meta-analyses, meta-regressions, and assessed publication bias and study quality. Analyses were two-tailed with α=0.05. Findings: 75 prospective studies were included (n=5,288, age=20.0 years, females=44.5%). Attenuated positive symptoms improved at 12 (Hedges’ g=0.753, 95%CI=0.495-1.012) and 24 (Hedges’ g=0.836, 95%CI=0.463-1.209), but not ≥36 months (Hedges’ g=0.315. 95%CI=-0.176–0.806). Negative symptoms improved at 12 (Hedges’ g=0.496, 95%CI=0.315–0.678), but not 24 (Hedges’ g=0.499, 95%CI=-0.137–1.134) or ≥36 months (Hedges’ g=0.033, 95%CI=-0.439–0.505). Depressive symptoms improved at 12 (Hedges’ g=0.611, 95%CI=0.441–0.782) and 24 (Hedges’ g=0.583, 95%CI=0.364–0.803), but not ≥36 months (Hedges’ g=0.512 95%CI=-0.337–1.361). Functioning improved at 12 (Hedges’ g=0.711, 95%CI=0.488–0.934), 24 (Hedges’ g=0.930, 95%CI=0.553–1.306) and ≥36 months (Hedges’ g=0.392, 95%CI=0.117–0.667). Remission from CHR-P status occurred in 33.4% (95%CI=22.6–44.1%) at 12 months, 41.4% (95%CI=32.3–50.5%) at 24 months and 42.4% (95%CI=23.4–61.3%) at ≥36 months. Heterogeneity across the included studies was significant and ranged from I2=53.6% to I2=96.9%. The quality of the included studies (mean±SD) was 4.6±1.1 (range=2-8). Interpretation: CHR-P individuals improve on symptomatic and functional outcomes over time, but these improvements are not maintained in the longer term, and less than half fully remit. Prolonged duration of care may be needed for this patient population to optimize outcomes. Funding: None.
UR - http://www.scopus.com/inward/record.url?scp=85108008173&partnerID=8YFLogxK
U2 - 10.1016/j.eclinm.2021.100909
DO - 10.1016/j.eclinm.2021.100909
M3 - Article
AN - SCOPUS:85108008173
SN - 2589-5370
VL - 36
JO - EClinicalMedicine
JF - EClinicalMedicine
M1 - 100909
ER -